logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Acceleron Pharma Inc.


USPTO Granted Patents = 172

% Expired Patents = 0.58



Forward Citations = 2,229

Loading Chart...
Loading Chart...

61 inventors (with patents filed for the assignee):

goldMedal Ravindra Kumar (120 out of 138 patents)

silverMedal Jasbir S Seehra (84 out of 112 patents)

bronzeMedal John L Knopf (76 out of 87 patents)

4.  Asya Grinberg (53 out of 67 patents)

5.  Dianne S Sako (39 out of 53 patents)

6.  Roselyne Castonguay (35 out of 35 patents)

7.  Robert Scott Pearsall (32 out of 32 patents)

8.  Jonathan Belk (10 out of 21 patents)

9.  Matthew L Sherman (10 out of 13 patents)

10.  Yossi Dagon (9 out of 10 patents)

11.  Kenneth M Attie (8 out of 8 patents)

12.  Gang Li (7 out of 7 patents)

13.  Rajasekhar Naga Venkata Sai Suragani (6 out of 6 patents)

14.  Nathan J Sharkey (6 out of 8 patents)

15.  Naga Venkata Sai Rajasekhar Suragani (6 out of 6 patents)


Core Competencies:
Pulmonary Hypertension
ALK7 Proteins
TGF-Beta Receptor
Anemia Treatments
Myelofibrosis
Muscular Dystrophy
Heterotopic Ossification
Kidney Fibrosis
Erythropoiesis
Sclerotic Disorders
Follistatin Polypeptides
Endoglin Peptides

172 patents:

1. 12678483 - METHODS FOR TREATING PULMONARY DISEASE WITH A LIGAND BINDING DOMAIN OF A TGF-BETA TYPE II RECEPTOR (2026-07-14),
2. 12673998 - ALK7 Binding Proteins and Uses Thereof (2026-07-07),
3. 12583906 - ACTRII PROTEINS AND USE IN TREATING POST-CAPILLARY PULMONARY HYPERTENSION (2026-03-24),
4. 12545736 - ACTRII-BINDING PROTEINS AND USES THEREOF (2026-02-10),
5. 12527839 - TREATMENTS FOR SYSTEMIC SCLEROSIS (2026-01-20),
6. 12421295 - TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof (2025-09-23),
7. 12365736 - ALK7 binding proteins and uses thereof (2025-07-22),
8. 12364736 - Methods for treating heterotopic ossification (2025-07-22),
9. 12343378 - Compositions and methods for treating pulmonary hypertension (2025-07-01),
10. 12258380 - ALK4:actriib heteromultimers and uses thereof (2025-03-25),
11. 12240887 - Variant ActRIIB proteins and uses thereof (2025-03-04),
12. 12195519 - Transforming growth factor-beta (TGF-beta) receptor type II fusion polypeptides (2025-01-14),
13. 12194076 - Methods and compositions for treating myelofibrosis (2025-01-14),
14. 12168683 - Binders of TGFβ-superfamily ligands and uses thereof (2024-12-17),
15. 12145970 - Twisted gastrulation polypeptides and uses thereof (2024-11-19),
Acceleron Pharma Inc., based in Cambridge, MA, specializes in the development of innovative therapies for serious and rare diseases, with a primary focus on pulmonary hypertension. The company is recognized for its research on ALK7 proteins and TGF-Beta receptors, which play critical roles in various conditions, including anemia, myelofibrosis, muscular dystrophy, heterotopic ossification, and kidney fibrosis. Acceleron's commitment to advancing treatment options positions it as a key player in the biopharmaceutical landscape.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Acceleron Pharma Inc.
172 Patents

#16 in Cambridge, MA

#129 in Massachusetts

#2,331 in US

#4,816 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Acceleron Pharma Inc.

Forward Citations = 2,229

61 inventors:

goldMedal Ravindra Kumar (120 out of 138 patents)

silverMedal Jasbir S Seehra (84 out of 112 patents)

bronzeMedal John L Knopf (76 out of 87 patents)

4.  Asya Grinberg (53 out of 67 patents)

5.  Dianne S Sako (39 out of 53 patents)

Please report any incorrect information to [email protected]
Loading…